Travere therapeutics announces pricing of public offering of common stock and pre-funded warrants

San diego, feb. 28, 2023 (globe newswire) -- travere therapeutics, inc. (nasdaq: tvtx) today announced the pricing of an underwritten public offering of 8,275,000 shares of its common stock at a price to the public of $21.00 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 1,250,000 shares of its common stock at a price to the public of $20.9999 per pre-funded warrant. the exercise price of the pre-funded warrants is $0.0001 per share. all of the shares and pre-funded warrants are being sold by travere. the gross proceeds from the offering are expected to be approximately $200.0 million, before deducting the underwriting discounts and commissions and offering expenses. the offering is expected to close on march 3, 2023, subject to customary closing conditions. in addition, travere has granted the underwriters for the offering a 30-day option to purchase up to an additional 1,428,750 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
TVTX Ratings Summary
TVTX Quant Ranking